Electronic Resource
2023 updated MASCC/ESMO consensus recommendations:prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting
| العنوان: | 2023 updated MASCC/ESMO consensus recommendations:prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting |
|---|---|
| المؤلفون: | Rapoport, Bernardo Leon, Herrstedt, Jørn, Snow, Rebecca Clark, Radhakrishnan, Venkatraman, Saito, Mitsue, Navari, Rudolph M., Smit, Teresa |
| المصدر: | Rapoport , B L , Herrstedt , J , Snow , R C , Radhakrishnan , V , Saito , M , Navari , R M & Smit , T 2024 , ' 2023 updated MASCC/ESMO consensus recommendations : prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting ' , Supportive Care in Cancer , vol. 32 , 36 . |
| بيانات النشر: | 2024 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Purpose: This review is an update of the MASCC/ESMO 2015 recommendations for the prophylaxis of acute and delayed nausea and vomiting induced by multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Methods: A systematic literature search was conducted using PubMed from June 1, 2015, through February 1, 2023. Results: We identified 56 references (16 were duplications or invalid), leaving 40 manuscripts for this search. The panel classified level I evidence (three manuscripts) and level II evidence (14 manuscripts). High-dose chemotherapy and stem cell transplant were discussed in four of these manuscripts, and multiple-day chemotherapy treatment in 15. Some manuscripts covered both topics. Additionally, a search for breakthrough nausea and vomiting resulted in 12 “hits.” No new relevant studies were identified. Conclusions: The recommendations for patients receiving high-dose chemotherapy with stem cell transplants and patients undergoing multiple-day cisplatin were updated. For patients receiving high-dose chemotherapy for stem cell transplant, a combination of a 5-HT3 receptor antagonist with dexamethasone and aprepitant is recommended. Olanzapine could be considered part of the antiemetic regimen. Patients receiving multiple-day cisplatin should receive a 5-HT3 receptor antagonist plus dexamethasone plus aprepitant plus olanzapine. For patients experiencing breakthrough nausea and vomiting, the available evidence suggests using a single dose of olanzapine daily for 3 days. |
| مصطلحات الفهرس: | 5-HT receptor antagonists, Breakthrough nausea and vomiting, CINV, High-dose chemotherapy, Multiple-day chemotherapy, NK receptor antagonists, article |
| URL: | |
| الاتاحة: | Open access content. Open access content info:eu-repo/semantics/openAccess |
| ملاحظة: | application/pdf English |
| Other Numbers: | DAV oai:pure.atira.dk:publications/5fe2ae5e-2824-4689-959d-c80c70b0fd65 1439557271 |
| المصدر المساهم: | UNIV OF COPENHAGEN From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1439557271 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |